Amanda Feilding
Executive Director and Founder
Data updated
Research Footprint
Amanda Feilding appears in 50 tracked papers (2010–2025), most studied alongside LSD, Psilocybin and Ayahuasca, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and Mendel Kaelen.
Publication Landscape
How the 50 papers Blossom tracks for Amanda Feilding line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Amanda Feilding's publishing grown?
SourcedTracked papers by publication year; 1 earlier paper published before 2011. Click a year for the running total.
Don't read as total output: only the 50 of 50 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Amanda Feilding publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Amanda Feilding publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Amanda Feilding (1943–2025) was a British drug policy reformer and the founder of the Beckley Foundation. Often described as the 'hidden hand' behind the psychedelic renaissance, she dedicated her life to the study of consciousness and the scientific validation of psychedelics. Through the Beckley Foundation, she collaborated on many of the first modern human studies with LSD, psilocybin, and MDMA.
Key Impact
Innocative figure in psychedelic research and founder of the Beckley Foundation.
Collaboration Network
77 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Amanda Feilding's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Amanda Feilding is associated with.